P

To study the oncologic and functional results of HIFU as a first-line treatment for localized prostate cancer.

Enrolment of patients between 2006 and 2011 for the first treatment against localized prostate cancer with HIFU (Integrated Imaging(®), EDAP-TMS, Vaulx-en-Velin, France).

The biochemical recurrence-free survival was calculated by using the Phoenix criterion (PSA>nadir+2ng/mL). The functional complications were assessed clinically and through standardised questionnaires.

The condition of 191 patients was assessed at a mean follow-up of 55. 5±22. 7 months. In 10,1% of the treatments, an incident during the medical procedure was observed with the volume of the prostate (P=0. 026) as risk factor. The overall survival, the survival and the metastatic free survival rate were respectively 89. 5%, 98. 4% and 97. 4%. The biochemical free survival rate for 5years was 87. 5%, 69% and 39% respectively for the low, medium and high-risk groups of d'Amico classification. Eighty-six percent of the patients with a PSA nadir≤0. 3ng/mL were relapse free at 5years. Whereas only 48% of the patients with a nadir>0. 3ng/mL did not. Only 17. 8% of the patients had a rescue treatment with an average delay of 31. 1 months. The urinary and sexual impairment was significant but 78. 1% of the patients were dry at the end of the study. The most common complication found in 18. 3% of the patients was the prostatic obstruction.

The oncologic and functional results of the HIFU seem similar to the other first-line treatments results and reveal that the HIFU is a therapeutic option for the treatment of prostate cancer in men over 70years.

5.

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. 2015 Oct 14 [Epub ahead of print]

B Rouget, G Capon, J C Bernhard, G Robert, P Ballanger, G Pierquet, H Bensadoun, J-M Ferrière, G Pasticier

CHU de Bordeaux, groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France. CHU de Bordeaux, groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France. , CHU de Bordeaux, groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France. , CHU de Bordeaux, groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France. , CHU de Bordeaux, groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France. , CHU de Bordeaux, groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France. , CHU de Bordeaux, groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France. , CHU de Bordeaux, groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France. , CHU de Bordeaux, groupe hospitalier Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France.

PubMed